Author:
Source
It hasn’t been the easiest of years for Johnson & Johnson (NYSE: JNJ), Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD). Shares of all three healthcare companies are trading flat or down amid challenges. Continued uncertainty regarding talc lawsuits is weighing on Johnson & Johnson. Amgen’s huge pipeline hasn’t been fully appreciated by the market, and Gilead’s settlement of an antitrust lawsuit resulted in lowering yearly earnings per share guidance.
However, all three also have great growth profiles that haven’t been fully factored into their shares. Each also offers an above-average dividend that will pay investors to wait until the stocks rise. Here’s why each pharmaceutical company is a solid buy right now.
Johnson & Johnson’s spinoff of its former Consumer Health division into Kenvue is complete, but investors appear not to have noticed the difference. That may be because talc lawsuit concerns continue to be in the news. J&J was just able to get a $223 million jury verdict in a talc case overturned by a New Jersey state appeals court. The company also said it is making a third attempt at a bankruptcy resolution of talc-related lawsuits through its LTL Management affiliate.